Abstract
Fourteen cases of chronic mylogencus leukemia were treated with 2 mg daily dosis of myleran (Group A), and their clinical and hematological states were compared with those of 13 cases who were treated with 4-8 mg daily dosis (Group B).
In the Group A, reduction of the peripheral leucocyte count and spleen size occured more slowly than in the Group B. Thrombocytopenia was observed not infrequently in the Group B, but was rare in the Group A.
Although the 2 mg therapy could not prevent the occurrence of the acute exacerbation, its incidence within 20 months after the start of the treatment was significantly reduced by the therapy, and 50 percent survival was prolonged from the 30 months of the Group B to the 60 months in the Group A.
From the above observations, it was considered that the therapy with 2 mg daily dosis was superior to that with 4-8 mg daily dosis in treating chronic myelogenous leukemia.
